Saitama, Japan

Fumie Kimura

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Riken Corporation. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fumie Kimura. Retrieved from https://idiyas.com/inventor/fumie-kimura-fsa5f6ss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fumie Kimura: Innovator in Biochemistry

Introduction

Fumie Kimura is a notable inventor based in Saitama, Japan. She has made significant contributions to the field of biochemistry, particularly in the development of novel enzymes. Her work has implications for various applications in biotechnology and medicine.

Latest Patents

Fumie Kimura holds a patent for PYRROLYSYL-TRNA SYNTHETASE. This invention showcases her expertise in enzyme engineering and its potential applications in genetic research.

Career Highlights

Kimura is affiliated with RIKEN Corporation, a prestigious research institution in Japan. Her role at RIKEN has allowed her to engage in cutting-edge research and collaborate with leading scientists in her field.

Collaborations

One of her notable collaborators is Atsushi Yamaguchi, who has worked alongside her on various projects. Their partnership has contributed to advancements in enzyme research and development.

Conclusion

Fumie Kimura's innovative work in biochemistry and her patent for PYRROLYSYL-TRNA SYNTHETASE highlight her contributions to science and technology. Her career at RIKEN Corporation and collaborations with other researchers further emphasize her impact in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…